Exact Sciences Corporation (NASDAQ:EXAS) is one of the best strong buy growth stocks to buy now. On August 21, Jefferies analyst Tycho Peterson reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS) and set a price target of $80.00.
Exact Sciences Corporation reported its fiscal Q2 2025 earnings on August 6, announcing a record total revenue of $811 million for the quarter, up 16% on a reported and core revenue basis.
The company raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively, and also announced a multi-year productivity plan targeting $150 million in annual savings by 2026.
Exact Sciences Corporation is a diagnostics and screening company that focuses on the early detection and prevention of particular types of cancer. It offers Cologuard, a non-invasive screening test for the early detection of colorectal cancer, pre-cancer, and Oncotype DX.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
